Multiple Sclerosis, Relapsing-Remitting
227
24
36
133
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
41 trials with published results (18%)
Research Maturity
133 completed trials (59% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
9.7%
22 terminated out of 227 trials
85.8%
-0.7% vs benchmark
26%
59 trials in Phase 3/4
31%
41 of 133 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 133 completed trials
Clinical Trials (227)
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients
RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial
Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
The Synergistic Effects of AIH and FES in Persons With MS
Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care
Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
Efficacy of Diet on Quality of Life in Multiple Sclerosis